share_log

HC Wainwright & Co. Maintains Buy on IO Biotech, Raises Price Target to $12

Benzinga ·  May 15 23:38

HC Wainwright & Co. analyst Emily Bodnar maintains IO Biotech (NASDAQ:IOBT) with a Buy and raises the price target from $8 to $12.

The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment